Skip to main content

Moleculin Biotech, Inc 8-K, filed Oct 30, 2026

Moleculin Biotech, Inc. (MBRX)

8-K 2026-10-30 For: 2026-10-30
View Original
Added on October 30, 2026

About this 8-K

Moleculin Biotech, Inc filed this 8-K on October 30, 2026.

Moleculin Biotech completed dosing in Part A of its pivotal Phase 2/3 MIRACLE trial of Annamycin plus cytarabine in relapsed or refractory AML. It remains on track to report comprehensive Part A data in the first quarter of 2027. AI summary

Items reported

  • Item 7.01: Regulation FD disclosure
  • Item 9.01: Financial statements and exhibits